Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Taucher, S; Steger, GG; Jakesz, R; Tausch, C; Wette, V; Schippinger, W; Kwasny, W; Reiner, G; Greil, R; Dubsky, P; Poestlberger, S; Tschmelitsch, J; Samonigg, H; Gnant, M; Austrian Breast and Colorectal Cancer Study Group-07.
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Breast Cancer Res Treat. 2008; 112(2): 309-316.
Doi: 10.1007/s10549-007-9844-9
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Samonigg Hellmut
- Schippinger Walter
- Study Group Mitglieder der Med Uni Graz:
- Hofmann Guenter
- Kronberger Leo
- Smola Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose To evaluate the impact that pre- and postoperatively administered chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF) and postoperative chemotherapy vs. postoperative chemotherapy alone have on long-term prognosis. Patients and Methods The ABCSG conducted a nationwide randomized phase III trial in high-risk endocrine non-responsive breast cancer patients comparing pre- and postoperative chemotherapy containing CMF as preoperative treatment vs. postoperative chemotherapy alone between 1991 and 1999. From 1996 the ABCSG-07 protocol was amended to also allow randomization of high-risk endocrine-responsive patients. Of 423 eligible patients with high-risk primary breast cancer, 203 patients were randomly assigned to preoperatively receive three cycles of CMF (cyclophosphamide, methotrexate, fluorouracil; 600/40/600 mg/m(2)) intravenously on day 1 and 8, while 195 patients received postoperative chemotherapy alone. In both groups, three cycles of CMF were given initially, and another three cycles of CMF were administered in node-negative patients, whereas node-positive patients received three cycles of EC (epirubicin, cyclophosphamide; 70/600 mg/m(2)). Results Overall response rate to preoperative chemotherapy with three cycles of CMF was 56.2%; complete pathological response was achieved in 12 patients (5.9%). Recurrence-free survival was significantly better in patients receiving chemotherapy postoperatively (HR 0.7, 0.515-0.955; P = 0.024). No survival difference was observed between the two therapy groups (HR 0.800, 0.563-1.136; P = 0.213). Discussion Preoperative chemotherapy with CMF has to be considered as insufficient in high-risk breast cancer patients. Delayed surgery and anthracycline-based chemotherapy result in shorter recurrence-free survival but not overall survival.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - administration and dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Breast Neoplasms - drug therapy Breast Neoplasms - pathology
- Chemotherapy, Adjuvant - methods
- Colorectal Neoplasms - metabolism
- Cyclophosphamide - administration and dosage
- Disease-Free Survival -
- Female -
- Fluorouracil - administration and dosage
- Humans -
- Medical Oncology - methods
- Methotrexate - administration and dosage
- Middle Aged -
- Prospective Studies -
- Risk -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- preoperative chemotherapy
- breast cancer
- CMF
- EC
- postoperative chemotherapy
- response